VBI Vaccines Reports Second Quarter 2023 Financial Results
-
PreHevbrio (Hepatitis B Vaccine [Recombinant]) global net revenue increased
48% quarter-over-quarter from Q1 to Q2 2023 - redefined, highly targeted commercial field team deployed at the end of Q2 -
Expanded hepatitis B collaboration with Brii Biosciences announced in July for
upfront, including a$15 million equity investment, and up to$3 million in potential additional milestones plus double-digit royalties$422 million -
Additional
gross proceeds from underwritten public offering added to balance sheet in July$20.5 million
“Q2 was a period of transition for VBI as we worked to more efficiently align resource deployment and headcount with the opportunities for value creation,” said Jeff Baxter, VBI’s President and CEO. “With, (i) the expansion of our hepatitis B partnership with Brii Biosciences, (ii) our internal workforce reduction largely complete, (iii) the redefined, highly targeted
Recent Key Program Achievements and Projected Upcoming Milestones
Hepatitis B (HBV)
PreHevbrio [Hepatitis B Vaccine (Recombinant)]
-
Global access continues to expand with:
-
June & July 2023: Launches in the
U.K. ,Netherlands , andBelgium through our marketing and distribution partnership with Valneva – brand name PreHevbri® [Hepatitis B Vaccine (Recombinant, Adsorbed)] -
July 2023: Exclusive licensing deal with Brii Biosciences (Brii Bio) announced for the development and commercialization of PreHevbri in the
Asia Pacific region (APAC), excludingJapan
-
June & July 2023: Launches in the
-
Global net product sales increased
48% from Q1 2023 with earned in Q2 2023$0.7 million -
Net product sales are net of the provision for discounts, chargebacks, rebates, and fees – in the aggregate, these discounts reduced sales by
in Q2 2023, from$0.5 million gross sales to$1.2 million net sales$0.7 million
-
Net product sales are net of the provision for discounts, chargebacks, rebates, and fees – in the aggregate, these discounts reduced sales by
-
June 2023: PreHevbrio was awarded part of the CDC 2023 Adult Vaccine contract for up to
$25.4 million - The CDC vaccine contract is established for the purchase of vaccines by immunization programs at the local, state, and national levels
-
Through our
U.S. partnership with Syneos, work has been underway to redefine theU.S. commercial account targeting strategy to better capitalize on the opportunities for, and access to, PreHevbrio, today – the transition to this new model started in February and was completed in June, with the new highly trained and experienced team now fully deployed -
Continued increase in use reflected among accounts that have made the switch to PreHevbrio, with a
46% increase in average order size from Q1 to Q2 2023 among such accounts - Contracting platform across multiple market segments continues to grow, including with retail partners, Integrated Delivery Networks (IDNs) and large hospital systems, military and federal facilities, prisons, and independent and public health clinics
-
U.S. coverage rates continue to be strong for PreHevbrio-specific Current Procedural Terminology (CPT) code across Medicare, commercial, and state Medicaid plans - Throughout H2 2023: Additional European market launches expected through partnership with Valneva
-
H1 2024: Availability expected in
Canada under brand name PreHevbrio [3-Antigen Hepatitis B Vaccine (Recombinant)]
VBI-2601 (BRII-179): HBV Immunotherapeutic Candidate
-
July 2023: Announced exclusive global licensing agreement with Brii Bio for the development and commercialization of VBI-2601
- This expanded partnership adds VBI-2601 to Brii Bio’s HBV portfolio, which, through a series of strategic investments and partnerships is among the most advanced in the chronic HBV field
- VBI will continue to share in the success of VBI-2601, with the potential to receive regulatory and commercial milestone payments, in addition to potential double-digit royalties on global sales of VBI-2601
-
Additional data from the two ongoing Phase 2 studies in
China andAsia Pacific are expected to be announced by Brii Bio in H2 2023
Glioblastoma (GBM)
VBI-1901: Cancer Vaccine Immunotherapeutic Candidate
- Q3 2023: First patients expected to be dosed in Phase 2b study of VBI-1901, an FDA Fast Track and Orphan Drug Designated cancer vaccine candidate, in recurrent GBM patients
- Q4 2023: Expected initiation of VBI-1901 study arm, as part of the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT), a Phase 2 adaptive platform trial, in combination with Agenus’ anti-PD-1, balstilimab, in primary GBM patients
COVID-19 & Coronaviruses
VBI-2901: Multivalent Coronavirus Vaccine Candidate
-
Q3 2023: Interim data readout from Phase 1 study of VBI-2901 expected – VBI-2901 is a multivalent, broad-spectrum eVLP vaccine candidate that expresses the SARS-CoV-2 (COVID-19), SARS-CoV-1 (SARS), and MERS-CoV (MERS) spike proteins, and was designed to increase breadth of protection against COVID-19 and related coronaviruses. VBI-2901 has been developed in collaboration with the National Research Council of
Canada (NRC) and is supported by funding from the Canadian Government’s Innovation, Science and Economic Development’s (ISED) Strategic Innovation Fund
Second Quarter 2023 Financial Results
-
Cash Position: VBI ended the second quarter of 2023 with
in cash as compared with$20.8 million in cash as of December 31, 2022. Cash position at June 30, 2023 does not include$62.6 million upfront payment, including$15 million equity investment, from the expanded Brii Bio partnership or$3 million gross proceeds from the underwritten public offering, both of which occurred in July 2023.$20.5 million -
Revenues, net: Revenues, net for the second quarter of 2023 were
as compared to$0.7 million for the same period in 2022. The revenue increase of$0.3 million 108% was a result of an increase in product sales of PreHevbrio in theU.S. , in addition to initial European product sales of PreHevbri to our partner, Valneva. -
Cost of Revenues: Cost of revenues was
in the second quarter of 2023 as compared to$3.5 million in the second quarter of 2022. The increase in the cost of revenues was due to increased product sales, direct labor costs, and inventory related costs for the Company’s 3-antigen HBV vaccine.$2.5 million -
Research and Development (R&D): R&D expenses for the second quarter of 2023 were
as compared to$3.3 million for the second quarter of 2022. R&D expenses were offset by$5.6 million in the second quarter of 2023 and$2.3 million in the second quarter of 2022 from government grants and funding arrangements.$1.0 million -
Sales, General, and Administrative (SG&A): SG&A expenses for the second quarter of 2023 were
as compared to$10.9 million for the same period in 2022. The decrease in SG&A expenses, partially offset by government grants and funding arrangements, was mainly a result of recent organizational changes that reduced our internal workforce, as announced in April 2023, and the redefined deployment strategy of our$15.1 million U.S. commercial field force and activities related to PreHevbrio. -
Net Cash Used in Operating Activities: Net cash used in operating activities for the six months ended June 30, 2023 was
compared to$40.9 million for the same period in 2022. The increase in cash outflows is largely a result of an increase in net loss, offset by non-cash reconciling items, mainly impairment charges and unrealized foreign exchange loss and the change in operating working capital, most notably in other current assets, accounts payable and other current liabilities. As announced on April 4, 2023, VBI continues to implement cost saving measures that are expected to reduce operating expenses from normal business in the second half of 2023 by 30$37.4 million -35% compared to the second half of 2022. -
Net Loss and Net Loss Per Share: Net loss and net loss per share for the second quarter of 2023 were
and$44.6 million , respectively, compared to a net loss and net loss per share of$5.18 and$45.7 million for the second quarter of 2022, respectively.$5.31 -
Net Loss and Net Loss Per Share, Excluding Impairment Charges and Foreign Exchange Loss: Net loss and net loss per share, excluding the non-cash impairment and foreign exchange loss, for the second quarter of 2023 were
and$18.7 million , respectively, compared to$2.17 and$23.8 million for the second quarter of 2022, respectively. See “Non-GAAP Financial Information” below for additional information regarding this non-GAAP financial measure, and “GAAP to Non-GAAP Reconciliation” for a reconciliation of this non-GAAP financial measure to net loss and net loss per share.$2.77 -
Impairment for the second quarter of 2023 was
as compared to$20.0 million for the second quarter of 2022.$0 -
Foreign exchange loss for the second quarter of 2023 was
as compared to$5.9 million for the second quarter of 2022. Certain intercompany loans between the Company and its subsidiaries are denominated in a currency other than the functional currency of each entity. The primary driver of the increase in foreign exchange loss was the impact of the relative strengthening of the$21.9 million U.S. and Canadian Dollars against the New Israeli Shekel upon translation of these intercompany loans.
-
Impairment for the second quarter of 2023 was
Use of Non-GAAP Financial Measures
Net Loss Excluding Foreign Exchange Loss and Impairment Charges and Net Loss per Share Excluding Foreign Exchange Loss and Impairment Charges are non-GAAP financial measures and are defined as net loss excluding foreign exchange loss and impairment charges. Net Loss and Net Loss Per Share, Excluding Impairment and Foreign Exchange Loss is not intended to replace net loss or net loss per share or other measures of financial performance reported in accordance with generally accepted accounting principles (GAAP). VBI’s management believes that the presentation of Net Loss Excluding Foreign Exchange Loss and Impairment Charges and Net Loss per Share Excluding Foreign Exchange Loss and Impairment Charges are useful to investors because management does not consider foreign exchange loss, which is primarily driven by changes in exchange rates related to certain intercompany loans, and impairment charges, which are non-recurring items, when evaluating VBI’s operating performance. Non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial results. The presentation of these non-GAAP financial measures should not be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with the Company’s financial statements prepared in accordance with GAAP. Reconciliations of the Company’s non-GAAP measures are included below.
The following represents a reconciliation of Net Loss to Net Loss Excluding Impairment Charges and Foreign Exchange Loss and Net Loss per Share Excluding Foreign Exchange Loss. See “Non-GAAP Financial Information” below for additional information regarding this non-GAAP financial measure, and “GAAP to Non-GAAP Reconciliation” for a reconciliation of this non-GAAP financial measure to net loss and net loss per share.
|
|
Three Months Ended June 30 |
|
|||
|
|
|
2023 |
|
2022 |
|
|
|
(Unaudited) (In 000’s except share and per share amounts) |
|
|||
|
Net Loss |
$ |
(44,628) |
$ |
(45,699) |
|
|
Impairment charges |
(20,000) |
|
- |
|
|
|
Foreign exchange loss |
|
(5,948) |
|
(21,895) |
|
|
Net loss excluding foreign exchange loss and impairment charges |
$ |
(18,680) |
$ |
(23,804) |
|
|
|
|||||
|
Weighted-average number of shares |
|
8,608,539 |
|
8,608,539 |
|
|
Net loss per share excluding foreign exchange loss and impairment charges |
$ |
(2.17) |
$ |
(2.77) |
|
About PreHevbrio [Hepatitis B Vaccine (Recombinant)]
PreHevbrio is the only 3-antigen hepatitis B vaccine, comprised of the three surface antigens of the hepatitis B virus – S, pre-S1, and pre-S2. It is approved for use in the
Please visit www.PreHevbrio.com for
PreHevbrio is indicated for prevention of infection caused by all known subtypes of hepatitis B virus. PreHevbrio is approved for use in adults 18 years of age and older.
Do not administer PreHevbrio to individuals with a history of severe allergic reaction (e.g. anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of PreHevbrio.
Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of PreHevbrio.
Immunocompromised persons, including those on immunosuppressant therapy, may have a diminished immune response to PreHevbrio.
PreHevbrio may not prevent hepatitis B infection, which has a long incubation period, in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.
The most common side effects (>
There is a pregnancy exposure registry that monitors pregnancy outcomes in women who received PreHevbrio during pregnancy. Women who receive PreHevbrio during pregnancy are encouraged to contact 1-888-421-8808 (toll-free).
To report SUSPECTED ADVERSE REACTIONS, contact VBI Vaccines at 1-888-421-8808 (toll-free) or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.
Please see Full Prescribing Information.
About VBI Vaccines Inc.
VBI Vaccines Inc. (“VBI”) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP (“eVLP”) platform technology, VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). VBI is headquartered in
Website Home: http://www.vbivaccines.com/
News and Resources: http://www.vbivaccines.com/news-and-resources/
Investors: http://www.vbivaccines.com/investors/
Cautionary Statement on Forward-looking Information
Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”). The Company cautions that such forward-looking statements involve risks and uncertainties that may materially affect the Company’s results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to, the impact of general economic, industry or political conditions in
VBI Vaccines Inc. and Subsidiaries |
|||||
Selected Condensed Consolidated Balance Sheet |
|||||
(In Thousands) |
|||||
|
June 30, 2023 |
|
December 31, 2022 |
||
|
(Unaudited) |
|
|||
Assets |
|
|
|
||
Cash |
$ |
20,840 |
|
$ |
62,629 |
Accounts receivable, net |
|
79 |
|
|
94 |
Inventory, net |
|
6,861 |
|
|
6,599 |
Prepaid expenses and other current assets |
|
4,111 |
|
|
8,368 |
Total current assets |
|
31,891 |
|
|
77,690 |
Property and equipment, net |
|
10,104 |
|
|
12,253 |
Intangible assets, net |
|
40,339 |
|
|
58,345 |
Goodwill |
|
2,175 |
|
|
2,127 |
Other non-current assets |
|
3,813 |
|
|
4,671 |
Total Assets |
$ |
88,322 |
|
$ |
155,086 |
|
|
|
|
||
Liabilities and stockholders’ equity |
|
|
|
||
Accounts payable |
$ |
7,353 |
|
$ |
12,973 |
Other current liabilities |
|
20,321 |
|
|
23,969 |
Total current liabilities |
|
27,674 |
|
|
36,942 |
Total non-current liabilities |
|
51,910 |
|
|
53,981 |
Total liabilities |
|
79,584 |
|
|
90,923 |
Total stockholders' equity |
|
8,738 |
|
|
64,163 |
Total liabilities and stockholders' equity |
$ |
88,322 |
|
$ |
155,086 |
|
|
|
|
|
|
|
|
|
|
||||
VBI Vaccines Inc. and Subsidiaries |
|
|
|
||||||
Condensed Consolidated Statement of Operations and Comprehensive Loss |
|
|
|
||||||
(In Thousands Except Share and Per Share Amounts) |
|
|
|
||||||
|
Three Months Ended June 30 |
|
Six Months Ended June 30 |
||||||
|
|
2023 |
|
2022 |
|
|
2023 |
|
2022 |
|
(Unaudited) |
||||||||
Revenues, net |
$ |
720 |
$ |
346 |
|
$ |
1,205 |
$ |
472 |
Operating expenses |
|
|
|
|
|
||||
Cost of revenue |
|
3,483 |
|
2,522 |
|
|
7,039 |
|
5,276 |
Research and development |
|
3,292 |
|
5,643 |
|
|
6,446 |
|
8,005 |
Sales, general and administrative |
|
10,917 |
|
15,084 |
|
|
24,201 |
|
26,014 |
Impairment charges |
|
20,000 |
|
- |
|
|
20,000 |
|
- |
Total operating expenses |
|
36,579 |
|
23,249 |
|
|
57,686 |
|
37,692 |
Loss from operations |
|
(36,972) |
|
(22,903) |
|
|
(56,481) |
|
(38,823) |
Interest income (expense), net |
|
(1,708) |
|
(901) |
|
|
(3,137) |
|
(1,841) |
Foreign exchange gain (loss) |
|
(5,948) |
|
(21,895) |
|
|
(12,761) |
|
(26,289) |
Loss before income taxes |
|
(44,628) |
|
(45,699) |
|
|
(72,379) |
|
(66,953) |
Income tax benefit |
|
- |
|
- |
|
|
- |
|
- |
Net Loss |
$ |
(44,628) |
$ |
(45,699) |
|
$ |
(72,379) |
$ |
(66,953) |
Basic and diluted net loss per share |
$ |
(5.05) |
$ |
(5.31) |
|
$ |
(8.41) |
$ |
(5.18) |
Weighted-average number of shares used to compute basic and diluted net loss per share |
|
8,608,539 |
|
8,608,539 |
|
|
8,608,539 |
|
8,608,526 |
Other comprehensive income (loss) -
|
|
6,670 |
|
19,236 |
|
|
13,269 |
|
24,339 |
Comprehensive Loss |
$ |
(37,958) |
$ |
(26,463) |
|
$ |
(59,110) |
$ |
(42,614) |
|
|
|
|
|
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20230814872763/en/
VBI Contact
Nicole Anderson
Director, Corporate Communications & IR
Phone: (617) 830-3031 x124
Email: IR@vbivaccines.com
Source: VBI Vaccines Inc.